Perioperative management of anticoagulation - Review of latest evidence

Arun Kannan, Chithra Poongkunran, Sundeep Shenoy, Aiden Abidov

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Periprocedural anticoagulation bridging is recommended to reduce the risk of thromboembolic events in patients at a higher risk of developing thromboembolism during the perioperative period. The optimal periprocedural anticoagulation strategy has not been established. Unfractionated heparin and low molecular heparin are used in preventing thromboembolism in the special population. Novel oral anticoagulants that directly inhibit thrombin (dabigatran) or factor Xa (rivaroxaban, apixaban) are shown as effective anticoagulants in preventing thromboembolism (venous thromboembolism) in various medical conditions. They have the advantage of having a faster onset, shorter half-lives, easier monitoring, and predicable doses. But there are disadvantages to newer anticoagulants such as the unavailability of definitive reversal agents and lack of data in patients with renal insufficiency. We review the latest evidence on the effects of newer oral anticoagulants in preventing thromboembolism and its bleeding risks.

Original languageEnglish (US)
Pages (from-to)e474-e484
JournalAmerican Journal of Therapeutics
Volume23
Issue number2
DOIs
StatePublished - Mar 1 2016

Fingerprint

Thromboembolism
Anticoagulants
Heparin
Perioperative Period
Factor Xa
Venous Thromboembolism
Thrombin
Renal Insufficiency
Hemorrhage
Population

Keywords

  • anticoagulants
  • bleeding
  • periprocedural anticoagulation
  • thrombosis

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Perioperative management of anticoagulation - Review of latest evidence. / Kannan, Arun; Poongkunran, Chithra; Shenoy, Sundeep; Abidov, Aiden.

In: American Journal of Therapeutics, Vol. 23, No. 2, 01.03.2016, p. e474-e484.

Research output: Contribution to journalArticle

Kannan, Arun ; Poongkunran, Chithra ; Shenoy, Sundeep ; Abidov, Aiden. / Perioperative management of anticoagulation - Review of latest evidence. In: American Journal of Therapeutics. 2016 ; Vol. 23, No. 2. pp. e474-e484.
@article{95316a00a6554dc890bfcf25274df410,
title = "Perioperative management of anticoagulation - Review of latest evidence",
abstract = "Periprocedural anticoagulation bridging is recommended to reduce the risk of thromboembolic events in patients at a higher risk of developing thromboembolism during the perioperative period. The optimal periprocedural anticoagulation strategy has not been established. Unfractionated heparin and low molecular heparin are used in preventing thromboembolism in the special population. Novel oral anticoagulants that directly inhibit thrombin (dabigatran) or factor Xa (rivaroxaban, apixaban) are shown as effective anticoagulants in preventing thromboembolism (venous thromboembolism) in various medical conditions. They have the advantage of having a faster onset, shorter half-lives, easier monitoring, and predicable doses. But there are disadvantages to newer anticoagulants such as the unavailability of definitive reversal agents and lack of data in patients with renal insufficiency. We review the latest evidence on the effects of newer oral anticoagulants in preventing thromboembolism and its bleeding risks.",
keywords = "anticoagulants, bleeding, periprocedural anticoagulation, thrombosis",
author = "Arun Kannan and Chithra Poongkunran and Sundeep Shenoy and Aiden Abidov",
year = "2016",
month = "3",
day = "1",
doi = "10.1097/MJT.0000000000000121",
language = "English (US)",
volume = "23",
pages = "e474--e484",
journal = "American Journal of Therapeutics",
issn = "1075-2765",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Perioperative management of anticoagulation - Review of latest evidence

AU - Kannan, Arun

AU - Poongkunran, Chithra

AU - Shenoy, Sundeep

AU - Abidov, Aiden

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Periprocedural anticoagulation bridging is recommended to reduce the risk of thromboembolic events in patients at a higher risk of developing thromboembolism during the perioperative period. The optimal periprocedural anticoagulation strategy has not been established. Unfractionated heparin and low molecular heparin are used in preventing thromboembolism in the special population. Novel oral anticoagulants that directly inhibit thrombin (dabigatran) or factor Xa (rivaroxaban, apixaban) are shown as effective anticoagulants in preventing thromboembolism (venous thromboembolism) in various medical conditions. They have the advantage of having a faster onset, shorter half-lives, easier monitoring, and predicable doses. But there are disadvantages to newer anticoagulants such as the unavailability of definitive reversal agents and lack of data in patients with renal insufficiency. We review the latest evidence on the effects of newer oral anticoagulants in preventing thromboembolism and its bleeding risks.

AB - Periprocedural anticoagulation bridging is recommended to reduce the risk of thromboembolic events in patients at a higher risk of developing thromboembolism during the perioperative period. The optimal periprocedural anticoagulation strategy has not been established. Unfractionated heparin and low molecular heparin are used in preventing thromboembolism in the special population. Novel oral anticoagulants that directly inhibit thrombin (dabigatran) or factor Xa (rivaroxaban, apixaban) are shown as effective anticoagulants in preventing thromboembolism (venous thromboembolism) in various medical conditions. They have the advantage of having a faster onset, shorter half-lives, easier monitoring, and predicable doses. But there are disadvantages to newer anticoagulants such as the unavailability of definitive reversal agents and lack of data in patients with renal insufficiency. We review the latest evidence on the effects of newer oral anticoagulants in preventing thromboembolism and its bleeding risks.

KW - anticoagulants

KW - bleeding

KW - periprocedural anticoagulation

KW - thrombosis

UR - http://www.scopus.com/inward/record.url?scp=84961677996&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961677996&partnerID=8YFLogxK

U2 - 10.1097/MJT.0000000000000121

DO - 10.1097/MJT.0000000000000121

M3 - Article

VL - 23

SP - e474-e484

JO - American Journal of Therapeutics

JF - American Journal of Therapeutics

SN - 1075-2765

IS - 2

ER -